Compare Braze Inc (BRZE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Braze Inc vs GeneDx Holdings Corp — how do they compare? Braze Inc trades at $27.52 (market cap $3.18B), while GeneDx Holdings Corp trades at $82.06 (market cap $2.44B). The key difference: Braze Inc is the larger of the two by market cap, and Braze Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| BRZE | WGS | |
|---|---|---|
Market Cap | $3.18B | $2.44B |
Sector | Technology | Technology |
52-Week High | $36.19 | $167.51 |
52-Week Low | $15.79 | $34.51 |
Enterprise Value | $2.87B | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Braze (BRZE) trades at $27.50, down 4.35% today but showing strong technical momentum with bullish moving averages. The company demonstrates impressive revenue growth, reaching $593.41 million in 2025 with 30% year-over-year expansion, though profitability remains elusive with a -15.51% net margin. Recent news highlights insider selling but also strong AI-driven customer engagement demand and four consecutive quarters of organic revenue acceleration.
The outlook remains positive with 96% analyst buy ratings and a $34.78 consensus target suggesting 26% upside. Key risks include persistent unprofitability despite growth and competitive pressures in the customer engagement software space. The stock's trajectory depends on continued revenue acceleration and eventual path to profitability.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
